Meet us at the Biotechgate Digital Partnering event 2020
Innovative AI-driven genomic and proteomic analysis platform for improving cell therapy and immuno-oncology
Proteona will take part in the Biotechgate virtual business development event, taking place from the 31st of August to the 3rd of September.
Biotechgate is an international database for biotech and Pharma business development. For this event, Biotechgate offers its digital partnering platform for free to support Life Science companies in response to COVID-19. More than 1000 delegates from biotech, medtech, and pharmaceutical companies will participate in the event.
Dr Andreas Schmidt, the CEO of Proteona, will be available during the event for further discussion.
Schedule a meeting now with Proteona through the conference networking platform!
For media queries, please contact:
Dr Andreas Schmidt
Proteona Pte. Ltd. is a biomedical company in Singapore, Germany, and the US that is pioneering the use of single cell proteogenomics to improve clinical outcomes in cancer. Using a combination of innovative single cell assays and AI-assisted bioinformatics, Proteona provides a comprehensive sample to answer service that enables users to phenotype cells using standard protein markers and gain a deeper understanding of cell activity based upon their gene expression profiles. Proteona is a spin-off from the National University of Singapore (NUS) and the Agency for Science, Technology and Research (A*STAR). Proteona is leading an international alliance to develop neutralizing antibodies against coronaviruses including SARS-CoV-2. In addition, Proteona supports partners developing COVID-19 therapies and vaccines by providing single cell immune profiling services.